Sales & Marketing

Biotech to obtain exclusive option for patients with select tumors.

Partnership enables rights to utilize therapeutic’s intravitreal retinotropic R100* vector.

Agreement to focus on the treatment of patients with advanced head and neck cancer.

In this insightful Q&A, Aaron Noll, MD, MS, OptimizeRx's senior AI solutions engineer, sheds light on how healthcare professionals leverage various information channels, the type of data they seek, and the role of AI in personalizing and optimizing healthcare communication.

Expansion to include treatment for LDL-C reduction in patients with primary hyperlipidemia.

Medication reportedly worth more than $7 billion.

Healthcare stakeholders suggest system changes, proving therapeutic value.

Company to invest proceeds in further R&D efforts.

Medication is currently the only cleared drug shown to reduce disease progression.

Newly-issued final guidance focuses on language used when communicating quantitative efficacy or risk information.

Through the power of large language models and generative AI, pharma and biotech companies are transforming medical information delivery by offering direct, trustworthy, and accurate answers to patients and healthcare providers, significantly reducing time and frustration.

Prices not likely to change upon release.

Deal comes amid collaboration on encapsulated cell therapies.

Investor claims agreement not suitable for shareholders.

Venture designed to streamline drug development and clinical trials.

Gallery showcases experience of living with generalized pustular psoriasis.

Pharmaceutical company expects deal to further augment capabilities.

Medication is the first of its kind approved for patients as young as 12.

Deborah Dunsire set to retire later this year.

Senior editor Fran Pollaro interviews Veeva's Paul Shawah about the dynamic future of field teams in biopharma. The chat highlights the transformative power of data and artificial intelligence (AI) in advancing precision medicine.

Atorvaliq indicated for the treatment of high cholesterol.

Biopharma to request second look at approval.

Drug expected to support children aged 4 and 5 with Duchenne muscular dystrophy.

Medications expected to improve blood sugar control in children 10 years and older.

Project intends to increase diverse representation in medical imagery.

Medicine created for patients with difficulty swallowing tablets.

Collaboration to focus on identifying clinical development candidates.

Group to be fully integrated into Verix lab.

Initiative to support developing manufacturers launch new products.

Collaboration to focus on personalized medicine in the United Arab Emirates capital.